SCHEMBL1925337

SCHEMBL1925337

NC(=O)c1[nH]cc(CCC(=O)O)c1-c1ccc(NC(=O)Nc2ccccc2F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.47
NPC1 O15118 8/20 0.46
RAB9A P51151 8/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
HTT P42858 4/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CYP1A2 P05177 1/20 0.44
CA9 Q16790 1/20 0.44
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
RIPK2 O43353 1/20 0.42
KDR P35968 5/20 0.42
KIT P10721 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925746 0.88 ITGB1 (0.52) NPC1RAB9ASMN1; SMN2HTTMAPT
SCHEMBL1924464 0.88 ALDH1A1 (0.38) PKMNPC1RAB9ASMN1; SMN2HTT
SCHEMBL1924459 0.88 KDM4E (0.46) NPC1RAB9APOLBMAPTMEN1
SCHEMBL1925383 0.86 RAB9A (0.53) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL1925914 0.85 CA12 (0.49) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL1925178 0.85 KDR (0.49) CA12CA1CA2CA9KDR
SCHEMBL1925038 0.84 ROCK2 (0.46) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL1923912 0.83 KDR (0.48) SMN1; SMN2POLBMAPTMEN1KMT2A
SCHEMBL1925334 0.83 EPHX2 (0.48) MAPTMEN1KMT2ACA12CA1
SCHEMBL1925903 0.83 NPC1 (0.51) PKMNPC1RAB9ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP claimed